U
ONCT

UBS’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

UBS’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$6K Buy
6
+3
+100% +$4.42K ﹤0.01% 9324
2014
Q2 		$6K Hold
3
– – ﹤0.01% 9385
2014
Q1 		$7K Sell
3
-11
-79% -$27.4K ﹤0.01% 9275
2013
Q4 		$32K Buy
+14
New +$32K ﹤0.01% 7566
2013
Q3 		– Sell
-9
Closed -$44.8K – 10789
2013
Q2 		$79K Buy
+9
New +$69.3K ﹤0.01% 6187

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS's ONCT Position: Q3 2014 in Review

UBS increased its Oncternal Therapeutics, Inc. Common Stock (ONCT) stake by 100% in Q3 2014, buying an estimated $4.42K and bringing the position to 6 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #9324.

UBS first reported a position in ONCT in Q2 2013 and has held it in 5 quarters since. The position peaked at $79K in Q2 2013. 38 funds tracked by Wall St. Rank hold ONCT as of Q3 2014.

  • UBS held 6 shares of Oncternal Therapeutics, Inc. Common Stock worth $6K as of Q3 2014.
  • UBS bought 3 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $4.42K.
  • Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9324 holding.
  • UBS first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 5 quarters since.
  • UBS's Oncternal Therapeutics, Inc. Common Stock position peaked at $79K in Q2 2013.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.